April 8, 2026 Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center Read more
March 26, 2026 Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 Read more
March 17, 2026 Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions Read more
March 10, 2026 Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress Read more
March 9, 2026 Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 Read more
March 3, 2026 Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share Read more
March 3, 2026 Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders Read more
February 24, 2026 Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee Read more
February 10, 2026 Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business Read more